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Cellular uptake and cytoplasmic release of liposomal antisense oligonucleotides (AsODNs), which can act as rate-limiting steps,
are still remained to be completely optimized. Here, the possibility of enhancing such processes at cellular and animal levels by
cineole, as a penetration enhancer, was investigated. A cationic nanoliposome containing an AsODN against PKC-𝛼 and a cineole-
containing nanoliposomewere prepared and characterized.The effect of nanoliposomal cineole on sequence-specific cytotoxicity of
nanoliposomal AsODN against A549, was studied in vitro (MTT, flow cytometry, fluorescence microscopy, and real time PCR) and
in vivo (xenograft lung tumor in nudemice) using different concentrations and treatment times. Results showed specific cytotoxicity
of nanoliposomal AsODN was increased significantly from 11% to 25% when A549 cells were exposed to 10 𝜇g/mL cineole for 1 or
4 hours. This inhibitory effect was further increased to about 40% when the concentration was increased to 40𝜇g/mL for 1 hour.
In animal studies, cineole significantly decreased the tumor volume (about 75%) and increased its doubling time from 13 days to 31
days. A linear relationship exists between cineole concentration and its enhancement effects. Finally it was concluded that cineole,
and possibly other membrane fluidizers, can improve nanoliposomal gene therapy at cellular and animal levels.
1. Introduction
Antisense oligonucleotides (AsODNs), targeting specific
gene or mRNA, are capable of potently downregulating
proliferation and invasion in human cancer cells.Theymainly
act through RNAse-H activation or hybrid arrest (i.e., steric
blockage of translation) [1, 2]. Being polyanionic and large,
AsODNs practically are unable to permeate cell membranes
well and, therefore, they have compromised biological activ-
ity. Rationally designed carriers can help to overcome these
restrictions [3].
Cationic nanoliposomes are among the most widely
used nonviral carriers for macromolecules. They encapsulate
nucleic acids efficiently through electrostatic interaction and
condense them to form complexes called lipoplexes [4].
Liposomal encapsulation of AsODNs improves their trans-
fection efficiency and increases their resistance to nuclease
degradation [5, 6]. These carriers are mainly internalized
into the target cells through endocytosis [7–9]. Afterward,
AsODNs have to be released from endosomal compartment
into cytoplasm throughmembrane destabilization and fusion
mechanisms. However, lysosomal degradation of AsODNs
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can occur especially if AsODNs fail to be released from endo-
somes at early stages as pH falls in endosomal compartment
later [10, 11]. After release, AsODNs may act in the cytoplasm
or may migrate from cytoplasm into nucleus [12].
Among the above-mentioned steps, cellular uptake and
release from endosomes are the most significant barriers
in antisense therapy [13, 14]. To overcome these barriers,
different strategies have been employed such as incorporat-
ing nonbilayer forming lipids (e.g., DOPE) into liposomes,
application of cell penetrating peptides (CPPs) [15–19], or
employment of physicalmethods such as ultrasound [20] that
somehow are difficult to be employed. However, despite all
of these efforts, the problem has remained to be completely
solved by a safe, easy, and economic method.
On the other hand, there are several molecules, called
penetration enhancers, that are widely used to diminish
the barrier function of different biological membranes (e.g.,
stratum corneum in skin) to facilitate drug delivery to and
through the tissue [21]. Some of these molecules work by
disruption of lipid bilayers, which are also present in the
liposomes, cell membrane, and endosomes. Therefore, it was
decided here to investigate the application of suchmembrane
fluidizing agents (penetration enhancers) as a novel strategy
for improving delivery of liposomal ODN, in both in vitro
(cell lines) and in vivo (animal) models. Among different
chemical penetration enhancers is cineole, which acts mainly
through lipid bilayer fluidization and its mechanism of action
is well documented [22–24] and was chosen for the present
investigation.
Cineole, the major component of eucalyptus oil, belongs
to one of the biggest class of skin penetration enhancers
(i.e., terpenes) and has been shown to increase permeation
of hydrophilic and lipophilic drugs through human skin [2,
25], lamellar model structures [22, 26], and rat skin [27].
Its mechanisms of action are said to be extraction of lipids
and keratin denaturation [28], increase in fluidity of lamellar
membranes [22, 29], and improving drug partitioning to core
of lamellar membranes [23, 30], most of which are expected
to act on liposomes.
In this investigation, based on earlier survey, PKC-𝛼 as an
impressive inhibitory target for gene therapy in adenocarci-
noma cells was selected.The impact of cineole on efficiency of
liposomal AsODNs against protein kinase C-𝛼 (PKC-𝛼) was
evaluated through studying molecular transport and viability
of human non-small-cell lung adenocarcinoma (A549) cells
and suppression of tumor growth in A549 xenograftmodel in
nude mice [31].
2. Experimental Section
2.1. Materials. DOTAP, PEG2000-DSPE, egg PC were
obtained from Lipoid GMBH (Ludwigshafen, Germany).
DSPC was purchased from Northern Lipids (Vancouver,
Canada). Cholesterol (Chol) was purchased from Sigma
Chemical Company (St. Louis, MO). A 20-mer phosphorot-
hioate oligodeoxynucleotide, 5󸀠-TsCsCs AsTsGs AsCsGs
AsAsGs TsAsCs AsGsCs CsGs-3󸀠 (AsODN) directed against
PKC-𝛼 mRNA, and its random or scrambled sequence
(ScODN), 5󸀠-CsGsAs GsCsAs CsGsCs AsGsTs AsTsCs
AsCsTs AsGs-3󸀠, that was used as a control oligonucleotide
(ScODN) were synthesized by Bioneer (Korea) [31].
Fluorescein isothiocyanate tagged phosphorothioate
oligonucleotide (FITC-ON) was synthesized and purified
by Synthegen (Houston, TX, USA). Fetal bovine serum,
Dulbecco’s modified Eagle’s medium, RPMI 1640 medium,
trypan blue stain, and trypsin-EDTA solution were
purchased from Gibco BRL. 1,8 cineole (>99%) and
MTT were obtained from Sigma Chemical Company (St.
Louis, MO). All other used reagents were of analytical grade.
2.2. Methods
2.2.1. Preparation and Characterization of Cationic Liposomes.
PEG stabilized ODN-encapsulated liposomes (also called
stabilized antisense lipid particles or SALPs) were prepared
by the method described previously [6, 32]. Briefly, ethanolic
lipid solution was injected into ODN solution (10 𝜇M) in
citrate buffer (pH = 4). Lipid mixture was composed of
DSPC/Chol/PEG lipid/DOTAP (20 : 45 : 10 : 25, mol %). Dial-
ysis was performed against citrate buffer for 2 hours and sub-
sequently HEPES buffered saline (HBS, pH = 7.4) overnight.
DEAE-Sepharose CL-6B gel chromatography column was
prepared according to the instructions of the manufacturer
and unencapsulated ODN was removed using this anion-
exchanger resin. The nanoliposomes were then stored at 4∘C
until use within one month.
Particle size and zeta-potential of SALPswere determined
by Malvern Zetasizer (UK). ODN content was measured
by spectrophotometry (Shimadzu, Japan) after solubilizing
nanoliposomes [32] and phospholipid content was deter-
mined after Bligh and Dyer lipid extraction [33] by Stewart
methods [34] (three replicates each). Nanoliposomal encap-
sulation efficiency at any step was then calculated using
EE% = [(C2/L2)
(C1/L1)
] × 100, (1)
where C2 and L2 are ODN and lipid content of nanolipo-
somes, at any given stage, respectively, and C1 and L1 are,
respectively, initial ODN and lipid content of nanoliposomes.
2.2.2. Preparation of Liposomal Cineole by Thin Layer Film
Hydration. Cineole is a lipophilic compound and it is not
possible to deliver it by simple aqueous solution. For in vitro
application of such compounds, DMSO or other organic
solvents are usually used to solve material in culture media.
For in vivo purpose (especially in our survey), however, it is
better to avoid organic solvents due to their cytocidal effect
and interference in experimental results [35]. As advantages
of liposome as vehicle for essential oils have been shown [36],
it was decided here to formulate cineole as nanoliposomes.
Cineole-containing nanoliposomeswere prepared by thin
film hydration method with modification of Sinico method
[36]. Briefly egg phosphatidylcholine (egg PC)/DOTAP/chol/
cineole (14 : 1 : 7 : 78mol%) were dissolved in 10mL chloro-
form and the solvent was evaporated in a rotary balloon and
shaked for 2 hours at 40∘C. The obtained lipid film was then
hydrated with HBS (pH 7.4) to form initial nanoliposomes at
40∘C. Nanoliposomes were then extruded (3 times through
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200 nm and 3 times through 100 nm) polycarbonate filter
membranes (Millipore, USA) and subsequently purified by
G50 Sephadex column to separate free cineole.
2.2.3. Cineole Assay and Encapsulation Efficiency. Cineole-
containing nanoliposomeswere destroyed in an equal volume
of methanol to give a clear solution and the solution was
then assayed for cineole by a GC method using a Shimadzu
gas chromatography system using BPX1 column and con-
nected to FID detector (Shimadzu Co., Japan). This method
employed a calibration curve in the range of 0.03 to 10mg/mL
using solution of cineole in water/methanol (50 : 50), 𝑛 = 3.
The encapsulation efficiency (EE %) of liposomal cineole was
calculated by (1).
2.2.4. Cell Culture Studies. A549 cells, obtained from Pasteur
Institute (Tehran, Iran), were grown in RPMI 1640 medium
supplemented with 10% heat-inactivated FBS, 100U/mL
penicillin, and 100 𝜇g/mL streptomycin. They were main-
tained at 37∘C in a 5% CO
2
-incubator (Heraeus, Germany).
Cell viability was evaluated either by cell count using trypan
blue stain 0.4% under inverted microscope (Leica, Germany)
or by MTT assay [37].
To determine enhancer dose, the cytotoxic effect of
liposomal cineole on cells was first evaluated at 1 to 40𝜇g/mL
cineole concentration and incubation time of 1 and 4 hours
followed by cell viability evaluation after 48 hours by MTT
assay.
For enhancement studies, the cells were first treated for
1 or 4 hours with nanoliposomal cineole at 1–10 𝜇g/mL or
1–40𝜇g/mL concentration (in nontoxic ranges). The super-
natants of cells were then removed and cells were treated
with nanoliposomal preparations containing either AsODN
or ScODN at 150 nM ODN in the culture medium for 48
hours. After this period, sequence specific-antisense activity
of nanoliposomal ODNs was evaluated by MTT. The same
experiments were performed in the absence of cineole as
control.
2.2.5. Flow Cytometry. Quantitative cellular uptake of lipo-
somes was evaluated by flow cytometry. 300,000 cells were
seeded in each well of 6-well plates (NUNC, Denmark). After
24-hour incubation, the cells were transfected for 4 hours
by 300 nM FITC-ODN containing liposomes either at 4∘C
or at 37∘C. Cells were cotreated in some wells with sodium
azide (10mM) as active transport inhibitor and in some wells
cells were treated with liposomal cineole (1%). Cells were
detached from the plates, suspended in culture medium,
and then centrifuged. Cell pellets were then reconstituted
in 500 𝜇L of either cold PBS or monensin solution (20𝜇M)
in PBS. Cells were kept cold (on ice) until the measure-
ment of the cell-associated fluorescence by FACSCalibur
dual laser flow cytometer (Becton Dickinson, USA). Cell
Quest software (Becton Dickinson, USA) was used for data
acquisition through FL1 (530 nm) and analysis for 10,000
gated events. Cell-associated fluorescence intensities were
expressed as the average of these measurements ± S.E.
(𝑛 = 3).
2.2.6. Fluorescence Microscopy. Transfected cells were fixed
with paraformaldehyde and then were permeabilized with
Triton X-100 (0.4%). Subsequently, the nucleus was stained
with DAPI (50𝜇M). Cellular internalization of liposomal
FITC-ODNwas studied byAxiovert fluorescencemicroscope
(Zeiss, Germany) using AxioVision software (Zeiss, Ger-
many).
2.2.7. RT-PCR Assay of Target Gene Expression. Cells were
seeded in 6-well plates one day prior to transfection. Total
RNA of 6 hours treated cells (with ODNs alone or ODNs +
liposomal cineol) was extracted with TRIzol reagent accord-
ing to the manufacturer’s instructions. RNA concentration
and purity were determined by UV-spectrophotometry at
260 nm. RNA quality was studied by 1% agarose gel elec-
trophoresis followed by ethidium bromide staining. Prior to
electrophoresis, RNA was treated with DNase and purified
with Qiagen RNAeasy mini column. One microgram of total
RNAwas first reverse-transcribedwith 2 𝜇L randomhexamer
to cDNA and then was applied for PCR amplification [30].
PCR amplification was run for GAPDH (glyceraldehyde-3-
phosphate dehydrogenase), as house-keeping gene, in PCR
thermal cycler (MJ Research, MD) [31]. A volume of 10 𝜇L
PCR reaction for PKC-𝛼 along with its respective human
GAPDHwas loaded into 1% agarose gel in Tris-borate EDTA
(TBE) buffer 0.5x and amplified segments were detected by
ethidium bromide staining. Data were analyzed using UN-
SCAN-IT software (Silk Scientific, Inc.). The experiment was
performed in triplicate.
2.3. In Vivo Studies
2.3.1. Tumor Induction in Nude Mice. Female Balb/c nu/nu
mice (6 weeks old, weighing 18 ± 2 g) were purchased from
Research Center for Science and Technology in Medicine in
Tehran University of Medical Sciences (Tehran, Iran) and
maintained at an animal facility in a light- and temperature-
controlled aseptic environment. The handling of mice and
experimental procedures were conducted in accordance with
the protocols of Ethics Committee of Shaheed Beheshti
University of Medical Sciences.
8 × 106 A549 cells were harvested and resuspended
in 200𝜇L of RPMI 1640 media. The cell suspension was
injected into the right flank of the mice subcutaneously to
induce the initial tumor [38]. Mice were then monitored
and checked for tumoral volume every other day until the
tumor volumes reached the suitable size of approximately
500mm3. Tumor size was measured using a caliper across
its two perpendicular diameters [39].The initial tumors were
then removed, cut into pieces, and then passaged into other
mice by implanting tumor pieces into the right flank of every
animal as secondary tumors (xenograft tumors). The growth
curve of the tumors and doubling time of their volume
were then evaluated using Skipper model [40]. When the
secondary tumor volumes reached a mean value of around
100mm3, the time was considered as time-zero and the mice
were randomly assigned to groups of 3 mice for further
studies and treatments as described later.
4 Journal of Nanomaterials
Table 1: Properties of prepared oligodeoxy nucleotide- (ODN-) and cineole-containing nanoliposomes.
Formulation Size (nm) Zeta potential (mV) Encapsulation efficiency (%)
ODN-containing liposomes 115 ± 5.0 0.8 ± 0.7 87.5 ± 3.8
Cineole-containing liposomes 128 ± 2.7 6.8 ± 0.6 67.7 ± 0.3
2.3.2. Animal Studies of Antisenses ODNs and Enhancement
Effect of Liposomal Cineole. The antitumoral effects of lipo-
somal antisenses and the enhancement effects of cineole
on this process were investigated in tumor-bearing mice.
Nanoliposomal formulation was applied intratumorally at
0.5mgODN/kg using approximately 100 𝜇L of nanoliposo-
mal suspension containing 100 𝜇g/mL antisense for each
mouse. Cineole-containing nanoliposome was used as pre-
treatment (pretreatment injection was selected based on
our finding in lab and comparison with cotreatment) by
applying 100 𝜇L of nanoliposomal cineole (80 𝜇g/mL) as
intratumoral injection 2 hours prior to nanoliposomal ODN
application. This process (application of cineole and ODN
nanoliposomes) was performed every 4 days for 12 days.
Volumes of tumors were measured 2-3 times a week from
time zero to 1 month after the first injection.
2.3.3. Hematoxylin and Eosin Staining. At the end of the
observation period, mice were sacrificed and tumors were
removed, cut, and fixed in 10% formalin prior to paraffin pro-
cessing and embedding for further pathological studies. Rou-
tine hematoxylin and eosin (HE) staining [41] was carried
out on harvested tumor samples. Slides were then observed
under light microscope and the images were captured and
analyzed for cell death pattern. Based on morphology of
cell and nucleus membranes and their content appearance, a
portion of dead cells (necrotic or apoptotic cells) in each slide
were measured.
2.4. Statistics. Data are presented as mean ± standard error
for 3 replicates unless indicated differently. Linear regression
and curve fitting were performed by Graphpad Prism soft-
ware (San Diego, CA). Statistical comparisons were made
using SPSS statistical software (version 18.0) through two-
sided ANOVA and Tukey’s post hoc test.The differences were
considered significant when 𝑃 < 0.05.
3. Results
3.1. Characterization of Liposomes. Prepared ODN-contain-
ing liposomes showed a nearly neutral zeta potential (0.8mV)
and size of about 115 nm (Table 1).These values did not change
significantly during 6 months of storage at 4∘C (𝑃 > 0.05).
The encapsulation efficiency of ODN-containing liposomes
was calculated to be more than 87%.
Cineole-containing liposomes showed size and encap-
sulation efficiency of about 130 nm and 68%, respectively
(Table 1). These particles showed a mild positive charge
(about 7mV, Table 1) that is expected to reduce their aggre-
gation and might improve their efficacy [41].
The size of both liposomes used in the present study (115
and 130 nm) is close to the optimum size for liposomal drug
delivery (around 100 nm) [42].
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Figure 1: Effect of concentration and exposure time on cytotoxicity
of nanoliposomal cineole against A549 cells in vitro. Data are
presented as mean ± standard.
3.2. Determination of Cineole Cytotoxicity and Enhancer
Concentration. Figure 1 shows the effect of liposomal cineole
on the viability of A549 cells in vitro. As is shown, cineole
did not affect cell viability for 1-hour pretreatment over
the whole concentration range used here (1 to 40𝜇g/mL).
However, after 4-hour pretreatment, although there is no
significant cytotoxicity below 10𝜇g/mL, the viability of cells
decreased significantly at higher concentrations of 20 and
40 𝜇g/mL. Segmental analysis showed that a linear rela-
tionship exists between cell viability and log concentration
(Figure 1). The slope of the corresponding line was defined
here as antiproliferative-concentration sensitivity (ACS) that
was −60 ± 5.5 in the range of 10–40 𝜇g/mL for 4-hour
pretreatment.The slope (ACS) for 1-hour pretreatment (1.9±
0.5) and 4-hour pretreatment below 10 𝜇g/mL (−5.6±3.1) was
not significantly different from zero (𝑃 > 0.05). Therefore, all
subsequent cineole-treatment protocols employed nontoxic
condition based on the above results.
3.3. Effect of Cineole on Liposomal ODN Cytotoxicity In Vitro.
Figure 2 provides the effects of different cineole concentra-
tions and treatment protocols on antiproliferative effects of
liposomal ODNs. Results showed that control nanoliposomal
ODN (ScODN) does not show a significant cytotoxicity in
the absence or presence of 1-hour cineole pretreatment over
1–40 𝜇g/mL. The relationship between cell viability and log
concentration was found to be linear with a slope (ACS) of
(−0.8 ± 0.7) that is not different from zero (𝑃 > 0.05). When
the pretreatment time was increased to 4 hours, the nanoli-
posomal ScODN showed a slight decrease in the cell viability
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Figure 2: Effect of cineole pretreatment on antiproliferative action
of nanoliposomal antisense oligonucleotide (AsODN) in compari-
son to its control (ScODN) at different treatment times. Data are
presented as mean ± standard error (𝑛 = 6).
upon cineole concentration increase (slope = −4.7 ± 0.2) and
the viability reached to a value of about 91% at 10 𝜇g/mL.
These data were used to select nontoxic concentration of
cineole to apply in gene delivery experiments.
Nanoliposomal antisense (AsODN) showed a 20% reduc-
tion in cell viability in the absence of cineole that was sig-
nificant in comparison to ScODN. Cineole treatment caused
a concentration-dependent increase in antisense effect for
both 1- and 4-hour pretreatment times (Figure 2). The cell
viability reached a value of about 70% at 10 g/mL and 55%
at 40 𝜇g/mL. The slopes of viability versus concentration line
were calculated to be −15.7 ± 0.7 and −18.1 ± 1.2 for 1- and
4-hour cineole pretreatments, respectively, indicating that
increased pretreatment time causes a slight increase in the
sensitivity.
3.4. Fluorescence Microscopy and Flow Cytometry. Figure 3
shows that cationic liposomes can increase the cellular uptake
of AsODN very significantly from 9.0 ± 0.5 in free ODN to a
value of 84.2 ± 3.9. Cineole was able to further increase the
cell-associated fluorescence of liposomal ODN to a value of
134.3 ± 6.5 (𝑃 < 0.05). In contrast, the effect of cineole on the
cellular uptake of free ODN was negligible (𝑃 > 0.05).
After decreasing the incubation temperature from 37∘C
to 4∘C, cell-associated fluorescence intensity of the SALPs
diminished to 22.8±5.2. Almost the same effect was observed
when the cells were coincubated with sodium azide at 37∘C
(intensity of 39.0 ± 4.3). Cineole treatment did not change
the cellular fluorescence intensity with these inhibitory con-
ditions (4∘C or in presence of sodium azide). The fluorescent
intensities in the presence of cineol at 4∘C or in the presence
of cineole and sodium azide were calculated to be 22.3 ± 1.7
and 46.9 ± 4.7, respectively that are comparable to the above-
mentioned values. Incubation at 4∘C or with sodium azide
is expected to block the cellular uptake of the liposomes.
With cineol
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Figure 3: Flow cytometric analysis of the cellular uptake of prepared
cationic liposomes (SALPs) containing FITC-labelled antisense
oligodeoxynucleotides (AsODN) in cineole-treated (dark bars) or
untreated (light bars) samples at 37∘C or 4∘C in the presence or
absence of sodium azide treatments. Data are presented as mean ±
standard error (𝑛 = 2). Data of untreated samples are from
Tamaddon. (From [43] with permission from the Corresponding
Author and based on the related Copyright Agreements with the
publisher).
These data confirms endocytosis as the main entrance route
of liposomal ODNs.
Figure 4 shows that the green fluorescence of FITC-ODN
probe is diffusively scattered in the cells transfected with the
ODN-containing liposomes (SALPs) (c), while no distinct
intracellular fluorescence was observed if the cells incubated
with free FITC-ODN at the same concentration (a). Cineole
treatment increased the intracellular trafficking of the SALP
(d) and the cell-associated fluorescence of FITC-ODN (b).
3.5. RT-PCR Determination of Antisense Activity. Specific
PCR products of 172 and 531 base pairs were obtained
for PKC-𝛼 and GAPDH (internal control), respectively.
Treatment with 300 nM AsODN inhibited the gene expres-
sion (39.0% ± 7.1%) while no obvious inhibition of PKC-
𝛼 was observed with ScODN. Coincubation of the cells
with 1% liposomal cineole at the similar SALP concentration
increased the sequence-specific inhibition of the target gene
by about 2 times to 82.5% (Figure 5, 𝑃 < 0.01).
3.6. Effect of Cineole on In Vivo Tumor Growth in Xenograft
Model. Tumor growth profile in nude mice (Figure 6(a))
showed that nanoliposomal antisense decreases the tumor
volume from 832 to 440mm3 after 30 days. Nanoliposomal
cineole further increased the antisense activity significantly
(𝑃 < 0.05) by decreasing the tumor volume twice more to a
value of 205mm3. Scrambled ODN-containing formulation
and liposomal cineole also decreased the tumor volume, but
the effect was not that significant (𝑃 > 0.05) (Figure 6).
Data were also interpreted according to tumor volume
doubling time (Figure 6(b)). Tumor volume doubling time
in control (nontreated) animals was calculated to be 9.6 ±
0.6 days. Nanoliposomal AsODN increased this doubling
time significantly (𝑃 < 0.05) to a value of 13.4 days. After
cineole treatment, the doubling time was further increased
(𝑃 < 0.01) more than twofold to 31.4 days. Liposomal
ScODN (negative control) did not change the doubling
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Figure 4: Epifluorescence microscopy study of FITC-antisense oligodeoxynucleotides (AsODN) cellular distribution. Cytoplasmic
distribution of fluorescein green fluorescence (right images) was demonstrated after 4-hour incubation with either free AsODN (a, b),
liposomal AsODN (c, d), cineole-treated free AsODN (b), and cineole-treated liposomal AsODN (d). Left images illustrate DAPI-stained
nucleuses of the same systems.
time indicating that the increased doubling time of AsODN
is related to sequence specific inhibitory effect. Liposomal
cineole was able to increase the doubling time marginally to
12.3 days.
3.7. Hematoxylin and Eosin Staining. Figure 7 illustrates HE-
stained images of tumor for different treatments.The severity
of cell death was increased upon cineole pretreatment
(Figure 7) and more than 84% of cells had died. In the
group that was treated with nanoliposomal AsODN alone,
visible areas of necrotic and apoptotic cells can be seen
in related slide and almost 32.4% of cells were dead (Fig-
ure 7). Only small punctuate necrosis and apoptosis (i.e.,
less than 3%) were seen in ScODN-treated group (negative
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Figure 5: RT-PCR determination of protein kinase C-𝛼 (PKC-𝛼)
expression. A549 cells were transfected with the liposomal antisense
(As) or scrambled (Sc) oligodeoxynucleotides (ODN). Cells were
incubated with either pure cell culture medium alone (left bars) or
cineole-containing cell culture medium (right bars). Quantitative
expressed target mRNA. GAPDH data are provided as control.
control, Figure 7) and no obvious necrosis and apoptosis
were observed in A549 tumors of untreated group (Figure 7).
Pattern of cell death and debris of dead cell imply that
apoptosis is probably responsible for tumor inhibition.
4. Discussion
Present cell culture studies showed that applied AsODN can
decrease cell viability, with minor effects from scrambled
antisense (control), revealing that the effect of applied anti-
sense on cell viability is through specific mRNA inhibition,
which is in good correlation with Tamaddon findings [43].
Animal data also revealed that nanoliposomal antisense
was able to decrease the tumor volume and increase its
doubling time. These findings are in agreement with Yazaki
et al. who showed that intraperitoneal administration of
phosphorothioate antisense oligonucleotides against PKC-
alpha mRNA were able to inhibit xenografted glial tumors in
nude mice [44] and that of Ying et al. who showed tumor
inhibition effect of Elk-1 (an antisense ODN against PKC-
alpha) in carcinoma, both in vitro and in nude mice [45].
Cineole pretreatment increased the antisense effect sig-
nificantly by decreasing the tumor volume and increasing its
doubling time (more than 200%) or decreasing cell viability
in cell culture. It has been shown that endocytosis and
interactions of liposomes with cytoplasmic and endosomal
membranes are themainmechanisms for liposomal antisense
delivery [9, 43]. On the other hand, cineole performs its
enhancement effect toward small molecules through either
complexation with small polar molecules [23] or lipid bilayer
fluidization [22, 46]. Between these two mechanisms, the
importance of complexation might be lower due to the
mechanism of entrance of these particles into the cell in
liposomal delivery. Therefore, it might be concluded here
that cineole exerts its action through lipid bilayers fluidiza-
tion. Such a fluidization can increase membrane fusion or
disruption at liposomes, cell membrane, and/or endosome
levels and, therefore, improve uptake of liposomes into the
cell and/or increase their endosomal escape. This proposed
mechanism is in agreement with increased deformability and
higher cutaneous uptake of cineole-containing liposomes in
comparison to control liposomes [47]. In this direction, it
has been shown that presence of 40mol% DOPE (a lipid
fluidizer) causes enhanced transfection efficiency of Gal
lipoplex in Hela cells [48]. The main action of DOPE is
enhancing fusion by producing hexagonal phases; therefore
DOPEdecreases the stability of liposomes due to its geometry
and it has been shown that in vivo application of DOPE is
limited because of its interaction with blood cells [49] and
instability of the liposomes [18]. It has also been shown that
partially substituted polylysine (bilayer destabilizer) causes
a dramatic increase by (3–4.5 orders of magnitude) of the
transfection efficiency of DNA/polylysine polyplexes [50].
Our results also show that the enhancement effect of
cineole is concentration-dependent, which is in good agree-
ment with concentration-dependent enhancement effect of
cineole toward permeation of 5-fluorouracil and oestradiol
through a lamellar liquid crystalline lipid model structure
[26]. In comparison to urea as penetration enhancer for
gene delivery cineol could improve transfection efficiency of
liposomal ODN by around 2-foldmore intensive [51]. Results
also showed that treatment time affects enhancement effect
of cineole, but its intensity was found to be less than cineole
concentration (Figure 2).
The present results also indicate that cell culture data
correlate well with animal studies in terms of enhancement
effect, indicating that cell culture studies might be used for
screening of enhancers against liposomal delivery.
Besides enhancement effects, cineole showed cytotoxic
effect against A549 cells at high concentrations and/or long
treatment times. This is in agreement with Bowen and Ali
who showed that some terpenes may show antiproliferative
effect in cancer cells [52].
Although the data obtained clearly indicates that cineole
has the ability to enhance the cellular delivery of liposomal
AsODNs and also improves their antitumor efficacy, we
assumed that at least the in vitro results should be extended to
a wider panel of cell lines to substantiate the conclusion that
cineole increase liposomal AsODNs delivery and antitumor
effects. Therefore, these steps were also implemented for
OV2008 (ovarian carcinoma) and A431 (epidermoid carci-
noma) as two control cell lines; and results (have not been
demonstrated here) also confirmed the above conclusion.
To conclude, the present results clearly show that cine-
ole and possibly other terpenes and chemical penetration
enhancers are able to increase nanoliposomal AsODN deliv-
ery and its antitumoral effect. In terms of drug delivery,
increased permeation means either more pharmacological
effect or less drug content for the same effect, both of
which will result in more economic systems for expensive
treatment methods like liposomal gene delivery. In this
direction, Dempsey et al. have shown that sublethal doses of
chemotherapeutic agents can be combined with membrane
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Figure 6: Tumor growth profile (a) and doubling time (b) as indicators of inhibitory effects of different antisense (As) or scrambled (Sc)
oligodeoxynucleotides (ODN) nanoliposomal formulations in the presence or absence of cineole in nude mice in comparison to untreated
control animal. Data are presented as mean ± standard error (𝑛 = 3).
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Figure 7: Hematoxylin/eosin staining (parallel to Annexin Kit selection) of untreated tumor (a) and tumor treated by nanoliposomal
antisense (b, c) or scrambled (d) oligonucleotides in the absence (b, d) or presence (c) of cineole.
fluidizing treatments (hyperthermia, benzyl alcohol, and
ethanol) to produce a significant increase in drug efficacy
and apoptosis [53]. Other enhancement methods are also
reported for enhancement of liposomal or nonliposomal
ODN delivery like sonophoresis [20], electroporation, com-
plex formation, or radiation [54, 55]. In comparison to such
methods, chemical penetration enhancers are considered less
invasive, readily available, easy to apply, and less expensive.
5. Conclusion
Present investigation clearly shows that cineole and possibly
other membrane fluidizing agents or penetration enhancers
can improve antitumor activity of nanoliposomal antisense
oligonucleotides, possibly through improved cellular delivery
and cytoplasmic release. Although several other enhance-
ment methods are available, such chemical enhancement
might provide more versatile, less expensive, and noninva-
sive approaches for gene delivery. This strategy can open
new era in the field of liposomal gene therapy. Further
investigations including intravenous applicability of cineole-
fluidized liposome in animal models and application of other
biocompatible membrane fluidizing agents are suggested and
are in progress in our laboratories.
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